Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen

Ann Oncol. 2009 Dec;20(12):2019-20. doi: 10.1093/annonc/mdp456. Epub 2009 Sep 21.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cell Differentiation*
  • Cisplatin / therapeutic use*
  • Humans
  • Male
  • Neuroendocrine Cells / pathology*
  • Orchiectomy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*

Substances

  • Antineoplastic Agents
  • Cisplatin